Dabigatran: Rational dose individualisation and monitoring guidance is needed

New Zealand Medical Journal

Volumn 125, Issue 1357, 2012, Pages

  Duffull, Stephen B ^a   Wright, Daniel F B ^a   Al Sallami, Hesham S ^a   Zufferey, Paul J ^b   Faed, James M ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITÉ JEAN MONNET   (France)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ATORVASTATIN; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FELODIPINE; GLYCOPROTEIN P; MACROLIDE; VERAPAMIL; WARFARIN;

ARTICLE; BLEEDING; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT MONITORING; PHARMACOGENETICS; PRESCRIPTION; PROTHROMBIN TIME; THROMBIN TIME; VENOUS THROMBOEMBOLISM;

EID: 84863520369     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Boehringer Ingelheim (N.Z.) Limited. PRADAXA data sheet. 1 July 2011.
2. Best Practice Advocacy Centre (BPAC). The use of dabigatran in general practice: a cautious approach is recommended. Best Practice. 2011;38:10-27.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009;361(12):1139-51.
4. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation. 2009;120:2006-11.
5. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb. Res. 2006;117:569-77.
6. Wajima T, Isbister GK, Duffull SB. A Comprehensive Model for the Humoral Coagulation Network in Humans. Clin Pharmacol Ther. 2009;86:290-98.
7. Pharmac. Media Release: 'Game changing' anti-clotting treatment funded. http://www.pharmac.govt.nz/2011/06/14/Dabigatran%20funded.pdf (Accessed October 17 2011).
8. Barras MA, Duffull SB, Atherton JJ, Green B. Individualized compared with conventional dosing of enoxaparin. Clin Pharmacol Ther. 2008;83:882-8.
9. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
10. The International Warfarin Pharmacogenetics Consortium. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. N Engl J Med. 2009;360:753-64.
11. van Walraven C, Jennings A, Oake N, et al. Effect of Study Setting on Anticoagulation Control. Chest. 2006;129:1155-66.
12. Jackson SL, Peterson GM, House M, Bartlett T. Point-of-care monitoring of anticoagulant therapy by rural community pharmacists: description of successful outcomes. Aust. J. Rural Health. 2004;12:197-200.
13. Gage BF, Eby C, Johnson JA, et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. Clin Pharmacol Ther. 2008;84:326-31.
14. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006;367:404-11.
15. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 2010;103:1116-27.
16. Troconiz IF, Tillmann C, Liesenfeld K-H, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J. Clin. Pharmacol. 2007;47:371-82.
17. Hamberg AK, Dahl ML, Barban M, et al. A PK-PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy. Clin Pharmacol Ther. 2007;81:529-38.
18. Lane S, Al-Zubiedi S, Hatch E, et al. The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors. Br. J. Clin. Pharmacol. 2011;DOI: 10.1111/j.1365-2125.2011.04051.x.
19. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103-11.
20. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallelgroup, single-centre study. Clin. Pharmacokinet. 2010;49:259-68.
21. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol. 2007;64:292-303.
22. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21:152-61.
23. Lenzini P, Wadelius M, Kimmel S, et al. Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. Clin Pharmacol Ther. 2010;87:572-78.
24. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
25. Tian R, Koyabu N, Takanaga H, et al. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm. Res. 2002;19:802-9.
26. van Ryn J, Litzenburger T, Waterman A, et al. Dabigatran anticoagulant activity is neutralised by an antibody selective to dabigatran in in-vitro and in-vivo models. J. Am. Coll. Cardiol. 2011;57(Supp 14):E1130.
27. Pharmac. Guidelines for management of bleeding with dabigatran. http://www.pharmac.govt.nz/2011/06/13/Dabigatran%20bleeding%20management.pdf (Accessed January 121 2011).